Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Pneumococcal Vaccine Market Witnesses Steady Growth with a CAGR of 5.3%, Projected to exceed US$ 13.5 billion by 2030

Prophecy_Market_Insights_Logo

News provided by

Prophecy Market Insights

May 17, 2023, 06:03 ET

Share this article

Share toX

Share this article

Share toX

COVINA, Calif., May 17, 2023 /PRNewswire/ -- According to Prophecy Market Insights "Pneumococcal Vaccine Market accounted for US$ US$8.1 billion in 2020 and is estimated to be US$ 13.5 billion by 2030 and is anticipated to register a CAGR of 5.3%"

What is Pneumococcal Vaccine Market?

Meningococcal disease is caused by bacteria called as Neisseria meningitidis and includes infection of spinal cord, brain lining and bloodstream. It usually spreads from nearby infected areas such as the nasal sinuses or from the cerebrospinal fluid.

Growing prevalence of meningitis has given positive impact on target market growth. Increasing immunization initiatives by government and regulatory authorities in prevention of Meningococcal disease is further, expected to fulfill the demand for Pneumococcal Vaccine Market growth.

What is Prophecy's Analyst View on Pneumococcal Vaccine Market?

Growing awareness among individual regarding Meningococcal disease has become a key factor in market growth. Presence of major key players and ongoing research and development activities is further, anticipated to increase the demand for Meningococcal Vaccine market growth over the forecast period.

Looking for More Information? Download the Free Sample Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4632

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2023 – 2032

Accounted in 2023

US$ US$8.1 billion

Estimated to be in 2032

US$ 13.5 billion

CAGR          

5.3 %

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By vaccine type- Pneumococcal conjugate vaccine and  Pneumococcal polysaccharide vaccine

By product type– Prevnar 13, Synflorix and Pneumovax 23

By sector– Public and Private

By distribution channel– Distribution partner companies, Non-governmental organizations, Government authorities

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Customization Scope

Avail of customized purchase options to meet your exact research needs.

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/4632

What are the Recent News of Pneumococcal Vaccine Market?

  • In March 2023, GSK announced its positive headline result from phase III clinical trial of 5 in 1 "MenABCWY" combination vaccine where vaccine candidate was well tolerated with Menveo and Bexcero safety profile consistent.
  • In October 2022, U.S. FDA (Food and Drug Administration) approved "Menveo" (a Meningococcal Oligosaccharide Diphtheria CRM197 Conjugate Vaccine by group A, C, Y, and W-135) for individual of 10 to 55 years old to prevent meningococcal disease.

Who should get vaccinated with a pneumococcal vaccine?

  1. Infants and young children: Routine vaccination is recommended for all infants and young children, typically using pneumococcal conjugate vaccines.
  2. Adults aged 65 years and older: One dose of pneumococcal polysaccharide vaccine (PPSV23) is generally recommended for adults aged 65 years and older.
  3. Adults with certain medical conditions: Individuals with specific chronic diseases, weakened immune systems, or other health conditions that increase the risk of pneumococcal infections may require pneumococcal vaccination.
  4. Adults with specific risk factors: Individuals with lifestyle factors (such as smoking or alcohol abuse) or occupational exposures that increase the risk of pneumococcal infections may also be recommended to receive pneumococcal vaccination.

How do pneumococcal vaccines work?

Pneumococcal vaccines work by introducing small pieces of the Streptococcus pneumoniae bacteria into the body. This stimulates the immune system to produce antibodies that can recognize and target the bacteria. These antibodies help prevent infection by blocking the bacteria from attaching to cells and enhance the immune response if the person is exposed to pneumococcus in the future. Pneumococcal vaccines specifically target common strains associated with pneumococcal diseases, providing protection against pneumonia, meningitis, and bloodstream infections caused by Streptococcus pneumoniae.

What are key benefits of the Pneumococcal Vaccine Market?

  1. Disease Prevention: Pneumococcal vaccines are highly effective in preventing pneumococcal diseases, including pneumonia, meningitis, and bloodstream infections caused by Streptococcus pneumoniae bacteria. Vaccination helps reduce the incidence and severity of these diseases, potentially saving lives and improving overall public health.
  2. Improved Public Health: By reducing the burden of pneumococcal diseases, the vaccine market contributes to improved public health outcomes. Vaccination not only protects individuals who receive the vaccine but also helps prevent the spread of pneumococcal bacteria within communities, thereby safeguarding vulnerable populations, such as infants, the elderly, and those with weakened immune systems.
  3. Reduced Healthcare Costs: Pneumococcal diseases can lead to significant healthcare expenditures due to hospitalizations, treatments, and associated complications. By preventing these diseases, the vaccine market helps reduce the economic burden on healthcare systems, insurance providers, and individuals, resulting in cost savings in the long run.
  4. Enhanced Quality of Life: Pneumococcal diseases can cause severe illness, long-term disabilities, and even death. By preventing these diseases through vaccination, the market improves the overall quality of life for individuals, families, and communities.
  5. Herd Immunity: Wide adoption of pneumococcal vaccination creates herd immunity, which provides indirect protection to unvaccinated individuals by reducing the circulation of pneumococcal bacteria within the population.
  6. Research and Development: The Pneumococcal Vaccine Market drives investment in research and development for new and improved vaccines.

Looking for More Information? Download the PDF Brochure Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/4632

What are the Opportunities in the Pneumococcal Vaccine Market?

  1. Increasing global demand for pneumococcal vaccines.
  2. Expansion into emerging markets with high disease burden and growing healthcare infrastructure.
  3. Collaboration with governments and participation in national immunization programs.
  4. Investment in research and development for new and improved vaccines.
  5. Development of combination vaccines to protect against multiple diseases.
  6. Targeting specific high-risk groups beyond infants and older adults.
  7. Exploration of alternative vaccine delivery methods for improved accessibility.
  8. Leveraging public-private partnerships to accelerate vaccine availability and affordability.

Key Questions Asked in Report:

  1. What is the current market size of the pneumococcal vaccine market?
  2. What are the major factors driving the growth of the pneumococcal vaccine market?
  3. What are the different types of pneumococcal vaccines available in the market?
  4. What is the market share of leading manufacturers in the pneumococcal vaccine market?
  5. What are the key trends and developments in the pneumococcal vaccine market?
  6. What is the projected growth rate of the pneumococcal vaccine market in the coming years?
  7. What are the key challenges and barriers faced by the pneumococcal vaccine market?

Immediate Download:

https://www.prophecymarketinsights.com/market_insight/buy_now/4632?licence=6350&report_type=Global+Pneumococcal+Vaccine+Market&v1_licence_type=press_id

Browse Other Related Research Reports from Prophecy Market Insights:

Foot and Mouth Disease Vaccine Market accounted for US$ 1.96 billion in 2020 and is estimated to be US$ 4.04 billion by 2030 and is anticipated to register a CAGR of 7.50%.

Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$ 69.0 billion by 2030 and is anticipated to register a CAGR of 6.0%.

Pediatric Vaccines Market accounted for US$ 3.06 Billion in 2022 and is estimated to be US$ 6.29 billion by 2030 and is anticipated to register a CAGR of 7.5%.

About Us:                                                                      

Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company's research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.

To know more        
Contact Us:
Sales 
Prophecy Market Insights
📞 US toll free: +1 860 531 2574
📞 Rest of world: + 91 7775049802
✉ Email- [email protected]
🌐 Website- www.prophecymarketinsights.com

Follow us on:

LinkedIn | Twitter | Facebook |Youtube

Logo: https://mma.prnewswire.com/media/2067755/Prophecy_Market_Insights_Logo.jpg

SOURCE Prophecy Market Insights

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.